Biomarkers Consortium - Identification and Validation of ctDNA Quality Control Materials

Measurement of biomarkers in blood and other fluids is key to fully realizing the benefits of precision medicine. The most widely used blood-based biomarker today is circulating tumor DNA (ctDNA), and there are an increasing number of technologies to enrich, isolate, expand and interpret ctDNA. This diversity, while excellent for innovation and providing important cancer diagnostic options to patients, clinicians, and researchers, presents multiple challenges to standardized use and interpretation of assay results. A lack of standardization makes it difficult to trust and fully understand the results of each individual assay. What is urgently needed are universally recognized reference materials that provide assurance all the testing steps were executed correctly, enable comparison between assays across different laboratories and platforms, and provide accurate results.

The ctDNA Quality Control Materials project, in partnership with commercial reference material manufacturers, seeks to develop a set of nationally recognized standards to enable the production of suitable reference materials that can be submitted for FDA clearance for widespread use in ctDNA testing. Once successfully developed and disseminated, such reference material will provide confidence in interpretation of ctDNA biomarker assay results, paving the way for more effective clinical research, therapeutic decision-making, regulatory evaluation, and reimbursement applications.

Development and production of FDA cleared ctDNA reference material for use across multiple assays and platforms will provide a pathway to accelerate regulatory approval for novel liquid biopsy technologies and their employment to aid patients. In addition, the process developed to authenticate production of these reference materials will serve as a prototype for the development and validation of reference materials for other assays evaluating genomic material.


  • Solicit support and input on the design of reference materials from stakeholders including industry, National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), National Institutes of Standards and Technology (NIST), American Society of Clinical Oncology (ASCO), College of American Pathologists and academic institutions.
  • Define key parameters and requirements for the reference material and intended use.
  • Work with commercial control companies to develop reference materials.
  • Conduct analytical validation studies using the materials as they are developed and assembled into final working reference materials.
  • Perform a clinical pilot study in internal and external academic and commercial laboratories to extend the commutability analysis and establish clinical value of the reference materials.
  • Orchestrate, manage and submit publications on developing ctDNA reference materials.


The FNIH currently seeks funding to support this program. 



Or, for more information on how to partner with us, please contact


American Society of Clinical Oncology
Association for Molecular Pathology
College of American Pathologists
Dana-Farber Cancer Institute
Frederick National Laboratory for Cancer Research
Harvard University
Horizon Discovery Ltd
Mayo Clinic
National Cancer Institute
National Institute of Standards and Technology
SeraCare Life Sciences, Inc.
Thermo Fisher Scientific
U.S. Food and Drug Administration


Dana E. Connors, Scientific Project Manager, Cancer;
Stacey J. Adam, Ph.D., Director, Cancer;